MDT News & Events

Reports Q2 revenue $8.7M vs $7.6M last year. Brent Ashton, Covalon's Chief Executive Officer, commented, "Covalon's second quarter of fiscal 2026 demonstrated strong year-over-year revenue growth of 15%, led by both the U.S. Vascular Access and Surgical Consumables and U.S. Advanced Wound Care sales channels. The Company's gross margin of 61.5% represents a 690-basis-point improvement from a year ago and is a testament to the work being done to drive accelerated growth of our most profitable products. Net income was $1.1 million, which was 155% greater than the same period last year."00000

Medtronic announced its intent to acquire SPR Therapeutics, a privately held medical technology company and a recognized leader in temporary, percutaneous peripheral nerve stimulation, or PNS, therapies for chronic pain management. The transaction consists of an upfront cash payment of approximately $650M for all the outstanding equity in SPR. The acquisition continues Medtronic's momentum in driving strategic deals that further build out the company's core franchises. Drawing on Medtronic's 50 years of neuromodulation leadership, including the industry's broadest pain therapy portfolio1, this planned acquisition will increase Medtronic's ability to reach and support more people with complementary, minimally invasive pain relief options earlier in their care continuum. This transaction is subject to customary closing conditions and regulatory approvals. The anticipated close date will fall within the first half of Medtronic's Fiscal Year 2027, which officially began on April 25. Until closing, Medtronic and SPR Therapeutics will continue to operate as separate and independent companies.